Log In
Print
BCIQ
Print
Print this Print this
 

ALV-003, ALV003

  Manage Alerts
Collapse Summary General Information
Company Alvine Pharmaceuticals Inc.
DescriptionCombination of a cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) engineered to degrade gluten into non-immunotoxic fragments
Molecular Target Gluten
Mechanism of ActionDegrades protein
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentPhase II
Standard IndicationCeliac disease
Indication DetailsTreat celiac disease
Regulatory Designation U.S. - Fast Track (Treat celiac disease)
Partner AbbVie Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today